← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

Profound Medical Corp. (PROF) 10-Year Financial Performance & Capital Metrics

PROF • • Industrial / General
HealthcareMedical DevicesOncology & Cancer Treatment DevicesRadiation Therapy Systems
AboutProfound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.Show more
  • Revenue $10M +41.2%
  • EBITDA -$31M -11.3%
  • Net Income -$26M +7.3%
  • EPS (Diluted) -1.07 +20.7%
  • Gross Margin 65.89% +8.2%
  • EBITDA Margin -300.81% +21.2%
  • Operating Margin -309.57% +22.1%
  • Net Margin -260.45% +34.4%
  • ROE -57.79% +15.8%
  • ROIC -200.82% -24.4%
  • Debt/Equity 0.08 -66.4%
  • Interest Coverage -
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Company is almost debt free
  • ✓Momentum leader: RS Rating 90 (top 10%)
  • ✓Strong 5Y sales CAGR of 19.5%

✗Weaknesses

  • ✗Negative free cash flow
  • ✗Shares diluted 16.9% in last year
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-
5Y19.49%
3Y13.94%
TTM51.42%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM-11.51%

EPS CAGR

10Y-
5Y-
3Y-
TTM39.55%

ROCE

10Y Avg-74.08%
5Y Avg-45.99%
3Y Avg-55.23%
Latest-62.17%

Peer Comparison

Radiation Therapy Systems
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
SRTSSensus Healthcare, Inc.81.47M4.9612.1071.31%-8.44%-5.87%0.01
CATXPerspective Therapeutics, Inc.184.36M2.48-2.02-100%-197.29%-42.77%0.01
TLSITriSalus Life Sciences, Inc.307.28M6.15-4.9258.99%-98.45%
PROFProfound Medical Corp.302.68M8.34-7.7941.23%-272.77%-130.59%0.08
DCTHDelcath Systems, Inc.354.29M10.21-11.0317.02%1.5%1.04%0.02
PTHLPheton Holdings Ltd Class A Ordinary Shares8.46M0.90-17.38-28.7%-91.16%-13.91%0.04
ARAYAccuray Incorporated98.61M0.87-56.132.68%-4.28%-31.22%2.17

Profit & Loss

Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Sales/Revenue+003.9M1.91M4.17M7.3M6.87M6.68M7.2M10.17M
Revenue Growth %----0.51%1.18%0.75%-0.06%-0.03%0.08%0.41%
Cost of Goods Sold+119.03K187.01K2.41M1.31M1.78M3.83M3.92M3.66M2.82M3.47M
COGS % of Revenue--0.62%0.68%0.43%0.52%0.57%0.55%0.39%0.34%
Gross Profit+-119.03K-187.01K1.49M604.82K2.39M3.47M2.95M3.02M4.38M6.7M
Gross Margin %--0.38%0.32%0.57%0.48%0.43%0.45%0.61%0.66%
Gross Profit Growth %--0.57%8.96%-0.59%2.95%0.45%-0.15%0.02%0.45%0.53%
Operating Expenses+8.09M11.64M15.51M15.43M17.29M22.34M33.24M35.15M33M38.17M
OpEx % of Revenue--3.98%8.08%4.14%3.06%4.84%5.26%4.58%3.75%
Selling, General & Admin4.39M4.2M7.84M7.89M7.9M12.43M17.97M17.93M18.62M22.02M
SG&A % of Revenue--2.01%4.13%1.89%1.7%2.61%2.68%2.59%2.17%
Research & Development3.7M7.43M7.66M7.54M9.4M9.91M15.28M14.69M14.38M16.15M
R&D % of Revenue--1.97%3.94%2.25%1.36%2.22%2.2%2%1.59%
Other Operating Expenses01.57K3.65K3.75K0002.52M00
Operating Income+-11.22M-15.64M-17.63M-14.83M-14.9M-18.86M-30.29M-32.13M-28.62M-31.47M
Operating Margin %---4.52%-7.76%-3.57%-2.58%-4.41%-4.81%-3.97%-3.1%
Operating Income Growth %-1.59%-0.39%-0.13%0.16%-0.01%-0.27%-0.61%-0.06%0.11%-0.1%
EBITDA+-11.14M-15.45M-16.75M-13.15M-13.39M-17.32M-28.41M-30.52M-27.47M-30.58M
EBITDA Margin %---4.29%-6.88%-3.21%-2.37%-4.13%-4.57%-3.82%-3.01%
EBITDA Growth %-1.62%-0.39%-0.08%0.22%-0.02%-0.29%-0.64%-0.07%0.1%-0.11%
D&A (Non-Cash Add-back)85.77K187.01K876.42K1.68M1.51M1.54M1.88M1.6M1.15M891.06K
EBIT-11.69M-15.75M-13.84M-14.32M-14.04M-21.03M-30.53M-28.21M-27.93M-26.48M
Net Interest Income+-3.95M-498.62K-970.25K-400.18K-675K149K136.78K882.59K872K1.37M
Interest Income99.24K117.25K101.58K355.2K363K692K203.2K1.05M1.64M1.37M
Interest Expense4.05M615.87K1.07M755.37K1.04M543K66.41K167.1K770K0
Other Income/Expense-1.1M-672.3K2.72M-247.72K-171K-2.71M-303K3.74M-81K4.99M
Pretax Income+-12.32M-12.14M-14.91M-15.07M-15.07M-21.58M-30.59M-28.38M-28.7M-26.48M
Pretax Margin %---3.82%-7.89%-3.61%-2.95%-4.45%-4.25%-3.99%-2.6%
Income Tax+-523.22K10.46K58.94K169.44K147K45K105K287K-128K-1.9K
Effective Tax Rate %0.96%1%1%1.01%1.01%1%1%1.01%1%1%
Net Income+-11.8M-12.15M-14.97M-15.24M-15.22M-21.62M-30.7M-28.67M-28.57M-26.48M
Net Margin %---3.84%-7.98%-3.65%-2.96%-4.47%-4.29%-3.97%-2.6%
Net Income Growth %-0.44%-0.03%-0.23%-0.02%0%-0.42%-0.42%0.07%0%0.07%
Net Income (Continuing)-16.38M-16.33M-18.82M-15.24M-15.22M-21.62M-30.7M-28.67M-28.57M-26.48M
Discontinued Operations0000000000
Minority Interest0000000000
EPS (Diluted)+-4.98-2.93-2.44-1.52-1.39-1.25-1.50-1.38-1.35-1.07
EPS Growth %0.87%0.41%0.17%0.38%0.09%0.1%-0.2%0.08%0.02%0.21%
EPS (Basic)-4.98-2.93-2.44-1.52-1.39-1.25-1.50-1.38-1.35-1.07
Diluted Shares Outstanding2.37M4.15M6.14M10.04M11.09M17.29M20.47M20.83M21.18M24.77M
Basic Shares Outstanding2.37M4.15M6.14M10.04M11.09M17.29M20.46M20.83M21.18M24.77M
Dividend Payout Ratio----------

Balance Sheet

Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Total Current Assets+15.08M16.72M14M27.84M22.84M97.74M77.02M62.02M41.9M69.06M
Cash & Short-Term Investments14.79M15.5M8.83M22.53M14.82M83.91M67.06M46.52M26.21M54.91M
Cash Only7.58M15.5M8.83M22.53M14.82M83.91M67.06M46.52M26.21M54.91M
Short-Term Investments7.21M000000000
Accounts Receivable05.7M3.57M1.52M3.31M7.43M1.41M6.34M7.29M7.04M
Days Sales Outstanding--334.27289.58289.84371.3574.88346.59369.51252.91
Inventory0310.11K1.14M2.67M3.67M5.33M7.4M7.94M6.99M5.8M
Days Inventory Outstanding-605.27172.27745.31751.72508.05689.13791.93905.57610.53
Other Current Assets100.39K518.49K458.07K224.87K1.03M1.07M1.15M000
Total Non-Current Assets+188.52K904.48K8.17M6.34M7.27M6.86M9.64M2.4M2.06M1.17M
Property, Plant & Equipment165.1K709.05K1.37M886.44K2.22M2.28M1.9M1.72M1.57M821.01K
Fixed Asset Turnover--2.84x2.16x1.88x3.20x3.61x3.89x4.59x12.38x
Goodwill002.71M2.5M2.63M2.68M2.69M000
Intangible Assets23.42K195.44K4.09M2.95M2.41M1.9M1.43M680K490K261K
Long-Term Investments0000003.62M000
Other Non-Current Assets0000000000
Total Assets+15.27M17.63M22.17M34.18M30.11M104.6M86.66M64.42M43.96M70.23M
Asset Turnover--0.18x0.06x0.14x0.07x0.08x0.10x0.16x0.14x
Asset Growth %9.38%0.15%0.26%0.54%-0.12%2.47%-0.17%-0.26%-0.32%0.6%
Total Current Liabilities+913.01K3.68M8.53M5.79M8.24M4.81M4.15M4.18M6.37M6.57M
Accounts Payable01.32M4.04M2.87M3.03M3.38M3.18M2.03M865K1.32M
Days Payables Outstanding-2.58K611.71802.93620.55322.31295.62202.74112.08138.61
Short-Term Debt206.6K2.14M3.74M983.52K4.17M312K249.66K523K2.1M1.74M
Deferred Revenue (Current)0192.91K191.9K229.48K504.93K358K476.35K471K721K419K
Other Current Liabilities706.41K29.28K586.19K1.48M521.75K744K247.66K621K1.42M1.03M
Current Ratio16.52x4.54x1.64x4.81x2.77x20.32x18.56x14.82x6.58x10.52x
Quick Ratio16.52x4.46x1.51x4.35x2.33x19.22x16.78x12.92x5.48x9.64x
Cash Conversion Cycle---105.16231.96421.01557.09468.39935.771.16K724.83
Total Non-Current Liabilities+4.29M2.91M2.4M8.84M7.48M2.44M2M8.23M6.36M3.25M
Long-Term Debt5.56M3.87M352.98K10.62M5.18M006.65M5M2.92M
Capital Lease Obligations000-2.82M1.64M1.36M1.13M817K504K203K
Deferred Tax Liabilities00-284.95K250.64K000059K0
Other Non-Current Liabilities-1.27M-961.24K2.04M-2.3M14.65K00073K71K
Total Liabilities5.21M6.59M10.93M14.63M15.71M7.25M6.15M12.42M12.73M9.81M
Total Debt+4.21M4.94M4.09M8.78M10.99M1.68M1.38M8.23M7.87M5.12M
Net Debt-3.37M-10.56M-4.74M-13.75M-3.84M-82.24M-65.69M-38.29M-18.35M-49.79M
Debt / Equity0.42x0.45x0.36x0.45x0.76x0.02x0.02x0.16x0.25x0.08x
Debt / EBITDA----------
Net Debt / EBITDA----------
Interest Coverage-2.77x-25.40x-16.45x-19.63x-14.36x-34.74x-456.12x-192.25x-37.16x-
Total Equity+10.06M11.04M11.25M19.55M14.39M97.35M80.51M52M31.22M60.42M
Equity Growth %6.35%0.1%0.02%0.74%-0.26%5.76%-0.17%-0.35%-0.4%0.94%
Book Value per Share4.252.661.831.951.305.633.932.501.472.44
Total Shareholders' Equity10.06M11.04M11.25M19.55M14.39M97.35M80.51M52M31.22M60.42M
Common Stock48.34M61.95M78.22M88.79M100.46M211.53M219.28M205.82M222.21M281.55M
Retained Earnings-39.72M-53.16M-71.79M-81.52M-101.07M-129.99M-160.48M-189.36M-217.35M-245.17M
Treasury Stock00-4.85M0000000
Accumulated OCI08.42K-46.07K-21.07K-90.37K4.57M4.74M16.84M5.57M2.74M
Minority Interest0000000000

Cash Flow

Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Cash from Operations+-4.94M-10.79M-11.81M-13.43M-15.45M-20.57M-22.36M-25.8M-22.61M-23.45M
Operating CF Margin %---3.03%-7.03%-3.7%-2.82%-3.25%-3.86%-3.14%-2.31%
Operating CF Growth %-0.72%-1.18%-0.09%-0.14%-0.15%-0.33%-0.09%-0.15%0.12%-0.04%
Net Income-11.8M-12.15M-14.97M-15.24M-15.57M-21.62M-30.7M-28.67M-28.32M-27.82M
Depreciation & Amortization85.77K139.13K693.31K1.23M1.55M1.54M1.88M1.6M929K936K
Stock-Based Compensation464.61K745.15K1.06M797.49K03.02M7.21M4.24M3.42M2.58M
Deferred Taxes-1.55M7.62K0-70.94K000000
Other Non-Cash Items7.54M617.44K1.9M847.17K1.72M1.13M132K2.66M828K255K
Working Capital Changes311.39K-151.93K-501.61K-990.83K-3.15M-4.63M-877K-5.63M540K591K
Change in Receivables1.1M-611.9K-3.17M1.15M-872.97K-3.85M2M-1.42M-956K186K
Change in Inventory0-310.11K-806.63K-1.62M-873.6K-2.14M-2.49M-1.86M353K656K
Change in Payables-65.16K577.17K2.68M-857.06K-18.63K102K-356K-566K1.35M815K
Cash from Investing+-6.49M6.63M-793.18K0-192.79K-350K-593K000
Capital Expenditures-120.35K-808.84K-369.5K0-192.79K-350K-32K000
CapEx % of Revenue--0.09%-0.05%0.05%0%---
Acquisitions----------
Investments----------
Other Investing07.44M0000-561K000
Cash from Financing+18.73M11.83M6.12M27.81M6.8M87.43M5.95M7.03M1.76M54.7M
Debt Issued (Net)----------
Equity Issued (Net)----------
Dividends Paid0000000000
Share Repurchases----------
Other Financing-553.18K-4.14M-604.21K-6.57M-1.27M11.52M6.33M114K2.67M-4.85M
Net Change in Cash----------
Free Cash Flow+-5.06M-11.6M-12.18M-13.43M-15.45M-20.92M-22.95M-25.8M-22.61M-23.45M
FCF Margin %---3.12%-7.03%-3.7%-2.86%-3.34%-3.86%-3.14%-2.31%
FCF Growth %-0.72%-1.29%-0.05%-0.1%-0.15%-0.35%-0.1%-0.12%0.12%-0.04%
FCF per Share-2.14-2.79-1.98-1.34-1.39-1.21-1.12-1.24-1.07-0.95
FCF Conversion (FCF/Net Income)0.42x0.89x0.79x0.88x1.01x0.95x0.73x0.90x0.79x0.89x
Interest Paid000000043K669K0
Taxes Paid000000055K160K0

Key Ratios

Metric2015201620172018201920202021202220232024
Return on Equity (ROE)-206.48%-115.14%-134.34%-99.01%-89.69%-38.7%-34.52%-43.27%-68.65%-57.79%
Return on Invested Capital (ROIC)-179.66%-327.19%-378.57%-180.77%-136.7%-110.22%-151.78%-168.85%-161.4%-200.82%
Gross Margin--38.18%31.66%57.26%47.56%42.95%45.22%60.87%65.89%
Net Margin---383.77%-797.88%-364.69%-296.03%-446.66%-429.11%-396.85%-260.45%
Debt / Equity0.42x0.45x0.36x0.45x0.76x0.02x0.02x0.16x0.25x0.08x
Interest Coverage-2.77x-25.40x-16.45x-19.63x-14.36x-34.74x-456.12x-192.25x-37.16x-
FCF Conversion0.42x0.89x0.79x0.88x1.01x0.95x0.73x0.90x0.79x0.89x
Revenue Growth----51.01%118.47%74.99%-5.9%-2.79%7.75%41.23%

Revenue by Segment

201920202021202220232024
Recurring - Non-Capital-----8.24M
Recurring - Non-Capital Growth------
Capital Equipment-----2.44M
Capital Equipment Growth------
Capital equipment--3.15M2M6.81M-
Capital equipment Growth----36.38%239.62%-
Recurring - non-capital--3.29M4.68M393K-
Recurring - non-capital Growth---42.03%-91.60%-

Revenue by Geography

201920202021202220232024
UNITED STATES-----7.35M
UNITED STATES Growth------
CALIFORNIA-----2.44M
CALIFORNIA Growth------
DELAWARE-----891K
DELAWARE Growth------
USA--2.09M3.4M5.13M-
USA Growth---62.44%50.99%-
Germany--1.43M1.8M1.84M-
Germany Growth---25.95%2.62%-
Canada--1.72M1.49M230K-
Canada Growth----13.57%-84.56%-
C3M4.76M----
C Growth-58.61%----
D1.89M1.47M----
D Growth--22.33%----

Frequently Asked Questions

Growth & Financials

Profound Medical Corp. (PROF) reported $15.4M in revenue for fiscal year 2024.

Profound Medical Corp. (PROF) grew revenue by 41.2% over the past year. This is strong growth.

Profound Medical Corp. (PROF) reported a net loss of $42.0M for fiscal year 2024.

Dividend & Returns

Profound Medical Corp. (PROF) has a return on equity (ROE) of -57.8%. Negative ROE indicates the company is unprofitable.

Profound Medical Corp. (PROF) had negative free cash flow of $37.5M in fiscal year 2024, likely due to heavy capital investments.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.